Jade Biosciences, Inc.

NASDAQ:JBIO

Biotechnology

Healthcare
$15.49 -1.25%

-$0.21 today

Market cap
$1.07B
Beta
1.45
P/E (TTM)
-7.4
EPS (TTM)
-$2.24
52W Low $6.67High $28.00

Volume 0.79M

Average 0.83M

JBIO Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Jade Biosciences, Inc.NASDAQ: JBIO

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 66.7% from a year ago

Common stock stood at $5K at the end of Q1 FY2026, up 66.7% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +35.7% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +66.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5K+0.0% QoQ
Last fiscal yearDec 2025
$5K+66.7% YoY
Year agoMar 2025
$3K+66.7% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+66.7%——
1 year+66.7%——
3-year CAGR+35.7%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
5K USD
Year-over-year change
+66.7%
4-year CAGR
+25.7%

Common Stock vs competitors

How JBIO compares with its peers on the latest reported figures

  • JBIO's Mar 2026 common stock of $5K is the 5th highest of the 9 companies compared; the peer median is $5.17K.
  • Its year-over-year change of +66.7% is the 2nd highest of 7, against a peer median of +21.7%.
  • Common stock amounts to 0.0% of total assets for JBIO, versus a peer median of 0.0%.
JBIO Competitors Peer median
Common Stock for JBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ELDNEledon Pharmaceuticals, Inc.Mar 2026$76K +26.7%+75.0%0.1%
VERAVera Therapeutics, Inc.Jun 2026$72K +12.5%+36.4%0.0%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$37K +42.3%+45.5%0.0%
MLTXMoonLake ImmunotherapeuticsMar 2026$7K +16.7%+9.9%0.0%
JBIOJade Biosciences, Inc.Mar 2026$5K +66.7%+35.7%0.0%
DWTXDogwood Therapeutics, Inc.Mar 2026$3.34K +1648.7%+17.5%0.0%
ACRSAclaris Therapeutics, Inc.Mar 2026$1K +0.0%+0.0%0.0%
KYTXKyverna Therapeutics, Inc.Mar 2026$1K ——0.0%
TRAXFirst Tracks Biotherapeutics IncMar 2026$0 ——0.0%
Peer median (excluding JBIO) $5.17K+21.7%+26.9%0.0%

Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents54.2M22.4M23.49M33.75M88.44M
Short-term Investments113.18M106.82M98.95M44.87M247.72M
Net Receivables00000
Inventory00000
Other Current Assets240K295K250K845K0
Total Current Assets174.33M131.5M124.23M80.12M336.16M
Property, Plant & Equipment (Net)728K1.25M902K215K0
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets302K2.56M2.28M013.62M
Total Non-current Assets1.03M3.8M3.19M215K13.62M
Total Assets175.36M135.3M127.42M80.33M349.78M
Account Payables1.21M2.58M2.4M224K2.15M
Short-term Debt192K385K420K417K0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities360K3.13M10.45M319K3.32M
Total Current Liabilities2.55M7.78M17.64M3.83M16.54M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities13K71K70K70K0
Total Non-current Liabilities395K776K325K70K724K
Total Liabilities2.95M8.56M17.96M3.9M17.26M
Common Stock2K2K3K3K5K
Retained Earnings(36.39M)(87.9M)(163.42M)(233.05M)(174.39M)
Accumulated OCI(59K)(466K)237K105K129K
Other Stockholders Equity00000
Minority Interest00000
Total Equity172.42M126.74M109.46M76.43M332.52M
Total Debt574K1.09M675K417K724K
Net Debt(53.62M)(21.31M)(22.82M)(33.33M)(87.71M)

Jade Biosciences, Inc.

NASDAQ:JBIO

Intrinsic Alpha fair value

Locked

Current Price

$15.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.